الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 158 |  |  |
| | | from | 158 | | |
Abstract
Background: Breast cancer represents the major cause of cancer-related mortality among women globally. Obesity is one of the risk factors for breast cancer, particularly in postmenopausal women. Adiposopathy causes hypertrophy, which promotes metabolic dysregulation, hypoxia, inflammation, insulin resistance, and altered adipokine production such as vaspin and omentin-1.
Aim: The objective of this study was to inspect the link between the vaspin rs2236242 and the Val109Asp (rs2274907) omentin gene polymorphisms and their serum levels with the incidence of breast cancer in postmenopausal women.
Methods: The gene polymorphisms of vaspin rs2236242 and Val109Asp (rs2274907) omentin were identified by T-ARMS-PCR and RFLP-PCR respectively. The glucose homeostasis traits, lipid profile, total antioxidant capacity, and circulating vaspin and omentin-1 levels were all assessed.
Results: The AT genotype of vaspin rs2236242 and the Val/Asp genotype of Val109Asp (rs2274907) omentin were more prominent in breast cancer patients than the TT and Asp/Asp genotypes respectively. Serum vaspin and omentin-1 levels were significantly lower in breast cancer patients.
Conclusion: The AT genotype of the vaspin rs2236242 polymorphism, the heterozygous Asp/Val genotype of the omentin-1 gene, and low serum vaspin and omentin-1 levels were more associated with breast cancer incidence. On the other hand, higher levels of serum vaspin and omentin appeared to protect against the incidence of breast cancer.